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Abstract 
The following literature review provides an account in support of the premise that the 
cystic fibrosis (CF) disease affects widespread areas of the body primarily due to the 
defective CFTR protein. Mutations in the CFTR gene lead to defects in CFTR protein 
that causes the disease. Lack of protein function or lack of functional protein cause 
variability in severity of the phenotype. The defective CFTR protein changes ion influx 
and efflux across the body’s cell membranes, which ultimately changes the internal 
environment of these cells. This change contributes to each cell’s production of proteins 
through transcription and translation. The simple changes in ion movement in and out of 
these cells have detrimental effects on the overall function of the cells. The cells create a 
system for maintenance of the body’s health, and if the cells do not function 
appropriately, the body fails to manage viral and bacterial infections. In this review, I will 
discuss how the defective CFTR channel works in the cells of the bodies of CF patients, 
and explain why the normal CFTR channel is essential for proper health and maintenance 
of the human body. In addition to the CFTR channel, other factors affect the severity of 
the disease. Genome-wide association studies explore other factors attributed to CF, 
including environmental factors, modifier genes, transcriptional regulation factors, and 
post-translational modifications. Potentiators and correctors target the CFTR channel in 
order to increase CFTR function, working alongside therapies in order to combat the 
effects of defective channels in CF patients.  
 
Introduction 
Cystic Fibrosis is an autosomal recessive disorder caused by mutations in the gene 
encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein (1, 
2). It is most common in individuals of Caucasian descent, and diagnosed most in 
childhood (3). Screening for CF occurs in infants and in the U.S, 1 in 3,500 neonates is 
diagnosed with Cystic Fibrosis (3). In order to manifest this CF phenotype, an individual 
must be homozygous for a defective CFTR gene, inheriting one mutated copy, or allele, 
of the gene from each parent (3). The disease causes a widespread effect in the body 
among organs such as the skin, lungs, pancreas, liver, and gastrointestinal tracts, and 
could cause multisystem organ failure in the body (1).  
 
In people with CF, the CFTR gene is defective due to mutations, which occur on 
chromosome 7, and this gene then affects the protein called CFTR (1). The defective 
CFTR protein results in the manifestation of CF (1). Dehydration of airway surface liquid 
causes persistent inflammation of the airways in the lungs (2).  Dehydration leads to a 
depletion of the periciliary layer and production of highly viscoelastic mucus, making the 
mucociliary clearance system ineffective (2). The CFTR protein, which normally shuttles 
sodium and chloride ions across the membranes of cells, is defective, acting as a 
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dysfunctional chloride channel which fails to appropriately balance water and electrolyte 
composition in the cells of the body (1, 2).  
 
The imbalance of essential ions in the body’s cells has deleterious effects, and could 
eventually destroy affected organs (1). Patients with CF become more prone to repeated 
infections by organisms due to the buildup of secretions in the lungs; these secretions 
lead to a reduction in bacterial clearance and lung damage (1). In the pancreas, a 
deficiency of digestive enzymes occurs, leading to badly absorbed undigested foods and 
malnutrition (1). Islet cells in the pancreas could become damaged with time, leading to a 
decrease in insulin and glucagon secretion; proper secretion of these essential hormones 
is important for the regulation of the body’s blood-glucose levels (1). In addition, 
cirrhosis, or the result of advanced liver disease could occur, as well as infertility in 
males (1).  
 
CFTR Gene History  
CF was first linked to another gene, called a PON gene, which confirmed that CF was a 
homogeneous genetic disease and that the CF gene could be identified by genetic linkage 
analysis with a high number of two-generation families (4). After the first DNA marker 
linked to CF was found, localization of CF to the long arm of chromosome 7 was then 
confirmed (4). In order to isolate this gene, techniques such as “chromosome walking,” 
“positional cloning,” and “gene hopping” were used to isolate and identify the CFTR 
gene (3). Evidence for the CFTR gene exists in the presence of the most common 
mutation, ∆F508, renamed F508del (4). This 3-base pair deletion was found on a rare 
extended chromosome (4). 
 
CFTR Gene Structure  
The CFTR protein is a cyclic adenosine monophosphate-regulated (cAMP-regulated) 
chloride ion channel composed of 1,480 amino acids (3).  It is a member of the ATP-
binding cassette (ABC) family and it spans 189 kb of genomic DNA at chromosome 
7q31 (5, 6). CFTR has tight tissue-specific regulation of expression (5). The active locus 
is in a looped conformation that incorporates distal regulatory elements into close 
proximity with the gene promoter (5). The cAMP-regulated anion channel is expressed 
primarily at the apical plasma membrane of secretory epithelia; by understanding CFTR, 
one can understand defects in cellular processing, translation, and chloride channel gating 
(4).  
 
CFTR Protein Channel Conductance 
The promotion of the CFTR gene normally results in expression of CFTR protein, which 
is a transmembrane channel that works to move chloride and bicarbonate ions into and 
out of the body’s cells (3). Cellular processing and chloride channel function are studied 
in order to understand the basic defect that causes CF (4). 
 
The CFTR protein is structurally unique. The large multi-domain glycoprotein is an ATP-
binding cassette (ABC) transporter composed of five domains: two transmembrane 
domains (TMD1/TMD2) that form the channel pore, one regulatory domain (R) that 
gates the channel by phosphorylation, and two nucleotide-binding domains 
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(NBD1/NBD2) that bind and hydrolyze ATP (3, 4). Mature, wild type CFTR appears 
compact and folded and is known for protease resistance (7). In contrast, an immature 
CFTR protein, or even one mutated by the F508del CFTR mutation, has an open 
conformation, and shows increased protease sensitivity (7).1 Classical channel opening 
occurs by phosphorylation of the R domain by protein kinase A and recruitment of ATP 
to the nucleotide binding domains NBD1 and NBD2 (3).2 When ATP binds at the 
interface between NBD1 and NBD2, the channel opens (8). When ATP hydrolyzes, the 
NBDs dissociate to close the channel (3, 8).  This concludes the process of channel 
“gating,” ultimately allowing for chloride transport and conductance in and out of the cell 
as shown in Figure 1 (3).  
 
The architecture of the CFTR protein results in ion transport via the channel and causes 
voltage-dependent open channel blockage (9). A wide range of organic anions are 
encountered in the cytoplasm of the cell (9). The channel is usually involved in secreting 
chloride and bicarbonate ions at hyperpolarized potentials, so it contains fixed positive 
charges that allow a capture of anions from the cytoplasm by electrostatic attraction (9). 
At the center of the pore lies a positive charge, which allows for attraction of anions (9). 
Beyond this point, anions pass into a narrow uncharged pore region that allows 
discrimination between different anions (9). At this point, anions are selectively filtered; 
the channel stops organic anions from leaving the cell, and inhibits especially large 
anions from passing into the central pore region (9).  
 
Normal CFTR Function  
The CFTR protein channel functions in conductance of ions in and out of the body’s 
cells, which is important for the body’s maintenance of water and solute concentrations. 
Active chloride efflux drives fluid secretion, while bicarbonate influx drives fluid 
transport across the cells of tissues such as pancreatic ducts, the gastrointestinal tract, and 
the duodenum (9). In the duodenum and pancreatic duct, the sodium bicarbonate in these 
secretions is very high and the bicarbonate drives fluid secretion (9). Water then follows 
this high solute transport into the epithelia (9). Anion secretion in the airways contributes 
to the formation and maintenance of a thin layer of liquid called airway surface liquid 
(ASL), which consists of a lower-viscosity perciliary liquid (PCL) next to the membrane 
which has beating cilia, and a higher-viscosity gel layer where mucins trap inhaled debris 
and microbes (9). Anion secretion becomes important here because it maintains the 
volume and composition of PCL (9). Sodium is absorbed via an epithelial sodium 
channel, while chloride is secreted and shuttled out of the cell by CFTR; both of these 
transport processes help to maintain this periciliary layer on which the essential 
mucociliary clearance of debris and bacteria depends (9).  
 
In the intestines, the secretion of salt and water is important for the maintenance of an 
aqueous environment that supports enzymatic activity, absorption of nutrients, and 
clearance of luminal contents (9). The proximal small intestine is the main site for 
                                                 
1Protease-an enzyme that breaks down proteins and peptides; proteolysis-the breakdown of proteins or 
peptides into amino acids by the action of enzymes 
2Phosphorylation-adding phosphate group(s); protein kinase A phosphorylates the CFTR channel so that 
ATP can bind to NBD1 and NBD2, opening the channel during gating 
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absorption; it takes in salt and secretes bicarbonate in order to act as a buffer for gastric 
acid (9). The sodium-hydrogen and chloride-bicarbonate exchanges handle salt and water 
balance (9). In the more distal part of the small intestine, CFTR is localized to the crypt 
cells and villi, and in the large intestine CFTR is localized to the crypt epithelium; 
sodium moves through the pathway just as it does in airway cells (9). In the pancreatic 
duct, CFTR couples with anion exchangers called SLC26A3 and SLC26A3 to generate 
sodium bicarbonate secretion for alkalinizing the duodenum, which drives pancreatic 
digestive enzymes to the lumen of the duodenum and allows for salivary clearance of 
mucins and enzymes (9).  
 
Defective CFTR Protein 
In 1983, Paul Quinton discovered that the chloride transport defect causes CF, and 
follow-up studies show evidence that sodium reabsorption was elevated in airways, and 
thus that sodium and chloride transport were both altered in CF airways (10). The 
equilibrium of absorption and secretion of sodium and chloride respectively is disrupted 
by mutations in the CFTR gene, resulting in the absence of functional CFTR-dependent 
chloride secretion (11). While chloride transport is defective, sodium absorption is 
functional and persistent, causing ASL dehydration (11). Meanwhile, the sodium channel 
becomes hyperactive, causing increased sodium and water absorption (12). 
 
In CF patients, the CFTR proteins on the plasma membranes of cells are defective or 
absent, and this compromises the formation of sufficient PCL (9). Chloride is not 
properly shuttled out of the cells, but the epithelial sodium channel continues to absorb 
sodium, resulting in a paucity of low-viscosity fluid on which effective mucus clearance 
thrives (9). Due to the lack of an effective system of mucociliary clearance, mucus 
accumulates and so does bacteria (9). These bacteria and infections block ducts of glands 
in the body and colonize airways, causing further loss of the clearance system and 
leading to ineffective innate immunity (9).   
 
The main function of the CFTR anion channel in the airway epithelia and glands of the 
submucosa is to control electrolyte transport, as shown in Figure 2, and subsequently 
regulate pulmonary host defenses (13).  This electrolyte transport controls the necessary 
airway surface liquid of airway epithelia (13). Studies show that patients with CF have 
reduced anion conductance, or chloride conductance, but that their sodium conductance 
does not increase at all. Increased voltage and current of Cystic Fibrosis responses to 
amiloride, an inhibitor of epithelial sodium channels (ENaC) are usually interpreted as 
epithelial hyperabsorption (13). However, a 2011 study by Itani et al attributed epithelial 
hyperabsorption to the loss of chloride rather than to increased activity of sodium 
channels (13). This study corresponds to previous studies of newborn CF pigs 
manifesting a defect in host defense against bacteria but not acquiring secondary 
manifestations of the disease (13).  The study by Itani et al shows that CF sweat gland 
ducts and airway glands of the submucosa having reduced anion transport but not sodium 
hyperabsorption (13). 
 
Disease pathology within affected organ systems depends on the contribution of CFTR 
function in salt and water secretion (9). It also depends on the extent of the consequences 
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of deficient CFTR and how CFTR is expressed in the body’s tissues (9). For example, as 
little as 20% impairment of chloride secretion is enough to cause obstruction of the vas 
deferens, whereas 50% impairment of CFTR activity is not detectable as a change in 
sweat chloride, and little CFTR activity produces a large decrease in sweat chloride levels 
(9). The function of the cells is important for the regulation of the body’s organ systems, 
and the core defect in the dysfunctional CFTR channel that affects proper cell function 
throughout the body is anion transport (9).  
 
CFTR protein synthesis 
Under usual circumstances, extracellular signals stimulate CFTR gene expression by 
promoting transcription of the CFTR gene into mRNA (3). The single strand template 
moves through nuclear pores in order to interact with ribosomes in the cytoplasm or on 
the rough endoplasmic reticulum (ER) (3). Transfer RNA is translated into nascent chains 
of amino acids (3).  Polypeptides are formed and assembled into the immature CFTR 
protein product, which is then folded within the lipid bilayer of the ER (3). The protein 
matures in the ER and the final CFTR protein is then transferred to the Golgi apparatus 
for post-translational modification and packaging into transport vesicles (3). The channel 
is moved or “trafficked” to the surface of the cell for final expression on the apical 
membrane of cells (3).  
 
Based on how long it takes for the CFTR protein to leave the ER, CFTR domain 
assemblage takes between 30 and 120 minutes, meaning that there has to be a distinct 
process in which folding occurs (14). Folding occurs by two steps that require ATP, one 
being integration into the bilayer of the ER and the other being conversion from an 
incompletely folded, ER-associated version of a protein to a properly folded, mature 
conformation that exits the ER and goes to the Golgi apparatus for processing (14). 
Mutations in the CFTR gene have an effect on every step in protein synthesis. For 
example, the F508del mutation prevents the completion of protein folding (14). 
Therefore, protein synthesis must be understood in order to recognize mutations, which 
cause phenotypic symptoms of the disease of CF (3). 
 
Causes of the Defective Channel: Mutations 
A mutation is a permanent change in the DNA sequence that makes up a gene; mutations 
of the CFTR gene lessen the proper function of the CFTR protein (7). There are over 
1,000 mutations identified thus far for the CFTR gene, and these are categorized in five 
different classes (1, 15): 
• Class I 
o Defective protein production; few or not functioning CFTR chloride 
channels (1, 15) 
o Nonsense mutation or frameshift mutation in DNA that causes an in-frame 
premature termination codon in the protein-coding region (8) 
o Results in premature end to translation of protein (8) 
o Unstable truncated and nonfunctional proteins are degraded before they 
can reach the cell membrane (8) 
o Accounts for 10% of all CF mutations worldwide (8) 
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• Class II 
o Defective processing so that CFTR does not reach the surface membrane 
where it normally functions (1,15) 
o Result in a protein whose processing is blocked in the ER, failing to 
progress to the Golgi apparatus (1, 15) 
o Improperly folded CFTR, resulting in premature degradation (8) 
o F508del is the most common mutation at 90% (1, 15, 18) 
 Incompletely glycosylated (1, 15)3 
 Results in an improperly folded protein that is retained in the ER, 
causing its breakdown by the ubiquitin proteosomal system, and a 
small amount of the mature protein reaches the cell surface (16) 
• Class III 
o Produces a protein that reaches its site of action on the cell surface but 
does not conduct chloride due to defective regulation (1, 8, 15) 
o Typically these mutations result in defects in CFTR regulation by ATP 
and phosphorylation (8) 
o Third most common G551D mutation is in 3% of all CF patients (8) 
 Substitutes glycine for aspartate at amino acid residue 551 (8) 
 G551D-CFTR protein is adequately folded and inserts 
appropriately into the plasma membrane, but fails to open because 
of defective regulation (8) 
 Interferes with NBD1 and NBD2 dimerization, ATP binding, and 
hydrolysis (8) 
o When rescued and inserted into the plasma membrane, F508del exhibits 
defective regulation and can also be classified as Class III (8) 
 
• Class IV 
o Reduced amounts of functional CFTR protein (1) 
o Causes defects in chloride channel conductance due to reduced single-
channel chloride ion conductance and open channel probability (8, 15) 
 R117H missense mutation affects 0.5% of CF patients worldwide 
(8) 
• Causes a substitution of arginine to histidine at residue 117 
• R domain is usually phosphorylated, and NBD1 and NBD2 
bind to ATP, but the opening time of the channel is 
reduced, therefore reducing chloride transport (8) 
• Class V 
o Less than 1% of patients with CF have this mutation type (8) 
o Normal plasma membrane CFTR is produced, but less protein made due to 
lack of transcriptional regulation (8, 15) 
o Influences the splicing machinery, or mRNA processing, and generates 
both abnormal and normal spliced mRNA, which vary in levels among 
patients and even organs within the same patients (15) 
                                                 
3glycosylation-an enzymatic process that attaches glycans to proteins, lipids, or other organic molecules 
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o Spliced variants cause a reduced number of functioning CFTR in the 
plasma membrane of the cell (15) 
o A455E is a common mutation (15) 
 
Less functioning CFTR in the body’s cells leads to a more severe phenotype of CF (1). 
Classes I-III are associated with more severe disease and higher mortality, as shown in 
Table 1 (1). Some mutations are more detrimental to the body’s cells than others (17). 
For example, the class II mutation type, which includes the most common F508del 
mutation, affects the actual amount of CFTR at the cell surface because an immature 
protein will be created (17). The ER retains and fails to fully process the protein, which is  
instead degraded by ER quality control (17). Not enough CFTR protein will be made, 
posing a detrimental problem for regulation and conductance of ions into and out of the 
cells (17). The F508del mutation can be contrasted to the R117H mutation in Class IV, 
which is a milder mutation, because the CFTR protein is available at the cell surface, yet 
it decreases channel conductance of chloride ions (17). CFTR has reached the cell surface 
and there is enough of it, yet it cannot function to its full capacity and poorly conducts 
ions instead (17). The varying clinical consequences of the R117H mutation may not be 
as detrimental as those of the disease-causing F508del mutation (17).  
 
Disease-causing mutations result in defective cAMP-regulated choride secretion in the 
body’s cells (17). Restoring the function of CFTR-mediated chloride transport could 
improve CF (17). There are mutation-specific therapies for each class that seek to repair 
CFTR function: 
 
• Class I: These treatments consist of aminoglycoside antibiotics and small 
molecules that camouflage premature stop codons, incorporating an amino acid 
into the sequence and allowing for translation to continue over premature stop 
codons to the normal termination of the transcript (17). The mechanism allows 
successful translation of mRNA into a full-length protein (17).  
 
• Class II: Correctors are used to treat this mutation type. Correctors are specific 
chaperones or small molecules that allow mutants to escape ER degradation and 
reach the cell surface (17).  
 
• Class III: Potentiators are CFTR activators that can overcome the channel gating 
and regulatory defects of CFTR mutants, which localize to the cell membrane 
(17).  Potentiators are compounds that increase chloride secretion only in the 
background of normal physiological control; ideally these should not regulate the 
cAMP pathway, but rather act on the channel itself (17).  
 
• Class IV: In order to compensate for less CFTR conductance, treatments include 
either increasing the cell surface density of these mutants in conjunction with 




• Class V: Splicing factors that correct missplicing or manipulate those that alter the 
balance of different splice forms must be increased (17). Increased levels of 
correct transcripts are promoted in CF patients who bear CFTR mutations that 
occur due to splicing errors (17). 
 
Internal Environment of Cells 
In addition to the regulation of chloride conductance, the CFTR protein also plays a role 
in fluid homeostasis and influences the inner workings of the cells (18). Cellular 
maintenance includes the transport of electrolytes (18). The main pathway that regulates 
CFTR activity is the elevation of cAMP and activation of protein kinase A (PKA), since 
PKA-mediated phosphorylation of CFTR opens the anion pathway in the channel and 
allows exit of chloride ions (18). The second messenger cAMP mediates the intracellular 
response to a wide range of cellular processes, some of which include gene expression, 
metabolism, and growth and division of the cell (19). The main effector of cAMP is 
PKA, a tetrameric enzyme in its inactive form that has two catalytic subunits (C) and one 
regulatory subunit (R) dimer. Once the R subunits are bound to cAMP, the C subunits are 
released and begin phosphorylation of downstream targets (19).  Different stimuli can 
cause an increase in intracellular cAMP, but in order for the cell to execute the 
appropriate job of responding to a specific stimulus, the proper subset of downstream 
targets must be phosphorylated. Therefore, compartmentalization of the cell’s 
components is important for successful stimulation and completion of the cAMP-
signaling pathway (19). 
 
An example of the importance of this pathway occurs in the F508del mutation. The 
protein is unable to reach the cell membrane and gets degraded by the ER, causing a lack 
of CFTR protein at the cell surface, thus failing to keep the cAMP-dependent chloride 
conductance going in affected tissues (18). Even with correctors of the F508del mutation, 
the channel has been shown to have regulatory defects like reduced channel gating. It has 
also been shown that when isolated, the F508del mutation maintains normal PKA-
dependent regulation (18). These data suggest that the intracellular milieu must play an 
important role in the ability of CFTR to respond to cAMP regulation (18). Therefore, the 
mutation does not simply cause a change in stability of CFTR but also is associated with 
a change in the activity of intact cells (18).  
 
In particular, CFTR activity depends on a high level of organization of cytoskeletal F-
actin (18). The multiprotein complex specifically in epithelial cells involves F-actin and 
scaffolding proteins, NHERF1 and ezrin. This complex maintains CFTR in restricted 
areas of the plasma membrane of cells, and also controls CFTR function (18). Ezrin is a 
kinase A anchoring protein, which tethers PKA in the vicinity of CFTR, allowing cAMP-
dependent chloride efflux to occur (18).  The complex also ties mutant CFTR to the actin 
cytoskeleton, keeping the CFTR stable and delaying internalization, allowing efflux to 
occur (18). Altered cytoskeletal organization in cells results in excessive cAMP in the 
cytosol, and less cAMP in the subcortical compartment of the cell (18). Excessive 
cytosolic cAMP might have debilitating effects such as an increased activation of the 
nuclear factor kappa-light-chain-enhancer of activated B cells, NF-κB, and cells in CF 
airway epithelial cells have been found to have the effect of constitutive NF-κB, 
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signaling hyper inflammation (18). The lesser amount of cAMP in the subcortical region 
of the cell may cause a deficient regulation of the movement of chloride ions out of the 
cell (18).  
 
Clinical Manifestations of CF 
Normally, the CFTR protein is effective at mucociliary transport, assisted by hydration of 
the ASL (3). Hydration of the ASL occurs through a gradient by efflux of chloride ions 
through CFTR channels, in addition to influx of sodium through epithelial sodium 
channels in the membrane (3). Lack of CFTR or defective protein causes less chloride 
efflux and unregulated hyperabsorption of sodium ions (3). An imbalance of osmotic 
gradient causes dehydration of ASL, increased mucus thickness and damaged 
mucociliary transport as shown in Figure 3 (3).  
 
Mucus is a complex fluid containing immunoglobulins, antiseptic enzymes, salts, 
proteins, glycoproteins and water (20). Mucus is secreted by mucous cells and has many 
important functions, one being defending against infectious agents (20). It is a dense, 
viscoelastic material that is stabilized by hydrogen bonding, electrostatic interactions, and 
hydrophobic interactions (20). The mucus of CF patients contains less water than normal, 
a high amount of debris, and is more viscous due to its high molecular weight (20). The 
thickening of mucus leads to abnormal clearance and also bacterial growth (20). Thick 
mucus can block airways, leading to bacterial infection, chronic local inflammation, and 
a decline of lung function (3). 
 
The goblet cells in the epithelia release these mucins, forming double-layered attached 
mucus also found in the stomach, colon, lungs and small intestine because it is easily 
removable mucus (21). Mucins are proteins that possess long domains with amino acids 
and O-glycans (21). Several types of mucins form the actual mucus gel, and these have 
one or more domains involved in binding (21). Bicarbonate may be the missing link 
between CFTR and blocked mucus (21). Bicarbonate is an ion that can pass through the 
CFTR channel; it neutralizes pH and removes Ca2+ in order to unpack mucin during 
secretion (21). High amounts of bicarbonate ion, which are normally provided by 
functional CFTR are necessary for proper unfolding of mucins during secretion (21). In 
patients with CF who have the F508del mutation, the mucus becomes dense, difficult to 
move, and remains stagnant (21). 
 
Defective CFTR affects the lungs not only with lung disease, but also with conditions 
such as acute lung injury (ALI) (22). One of the major mechanisms that causes the 
removal of edema fluid from the alveolar air space of the lungs in people with ALI is the 
active transport of sodium and chloride ions across the alveolar type I and type II cells in 
the lungs (21). This creates an osmotic gradient for the reabsorption of water to occur 
(22). A 2013 study by Roux et al provides a link between CFTR and other conditions 
such as ALI that can occur as a result of main dysfunctional protein channels. Results 
show that if there is inhibition of the CFTR channel and the epithelial sodium channel 
(ENac), failure to produce alveolar fluid clearance causes morbidity and mortality in 
affected individuals (22). 
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In the absence of CFTR, mucus accumulates in the intestines, providing a home for 
microbes to colonize (23). In previous studies using CFTR knockout animals, 
mycobacterial species have been found in antibiotic-resistant infections of the skin, lungs, 
and gastrointestinal tract, showing that without the CFTR channel, bacteria flourish in 
areas of mucus that have accumulated in the body (23). Defective secretion of digestive 
enzymes and resulting fat malabsorption in the gastrointestinal system demonstrate a 
failure to thrive in addition to excess fat in the feces (3). Also, ionic imbalance in the 
biliary tract may lead to increased risk of gallstone and hepatobiliary disease (3). Again, 
the CFTR channel is necessary for proper conductance within cells of the human body 
(23). 
 
In addition to the airways, lungs, and gastrointestinal tract, the glands of the body also 
require proper chloride conductance. In a healthy person, the CFTR protein is responsible 
for reabsorption of chloride, and subsequently, sodium in the reabsorptive duct of the 
sweat gland (3). Lack of CFTR protein or protein function causes salty beads of sweat to 
rise in individuals with CF (3). Sodium is excessively secreted by sweat glands, which is 
why most patients diagnosed with CF have high sweat chloride levels (3).  
 
The defective CFTR channel and effect on improper ion conductance in and out of the 
body’s cells affects not only the respiratory, digestive, and endocrine systems but also the 
reproductive system. Females with CF may experience the thickening of cervical mucus, 
which could cause infertility (3). Most males with CF have a developmental defect, 
which blocks the transport of spermatozoa from the testes or epididymis to the vas 
deferens (5). This congenital bilateral absence of the vas deferens causes azoospermia, or 
lack of sperm in the semen of males (3). 
 
Nervous System 
The defective CFTR protein affects the peripheral and central nervous systems. CF 
patients have been found to have peripheral nervous system abnormalities such as 
neuropathy, and the CFTR gene has been expressed and active in Schwann cells (24). 
Mutations cause a loss of CFTR, which results in myelin sheath abnormalities of these 
Schwann cells (24). A 2013 study by Reznikov et al shows similar abnormalities to those 
found in neuropathies in knockout CFTR pigs (24). Chloride channels stabilize 
membrane potential in Schwann cells, so if the CFTR channel were removed or 
defective, changes in ionic flow across these cells would rapidly occur (24). In addition to 
abnormalities in Schwann cells, a delay in conduction of the vestibulocochlear nerve was 
found, as were axon density reduction and a decrease in speed of the trigeminal and 
sciatic nerve impulses (24). People with CF have also had an unusual cholinergic and 
adrenergic sensitivity in pupil constrictions, sweat and salivation, regulation of blood 
pressure levels, and constriction of the bronchioles (24).  
 
The peripheral nervous system also contains neurotransmitters, which allow the 
transmission of signals from one neuron to the next (25).  Acetylcholine is a 
neurotransmitter that participates in paracrine and autocrine signaling in uptake of 
choline; signaling occurs by mediation mechanisms such as facilitated diffusion, sodium-
independent transporters including organic cation transporters, and sodium-dependent 
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choline transporters (25). Organic cation transporters are involved in choline transport 
across the plasma membrane; CFTR function might contribute to altered choline 
transport in non-neuronal cells through interference with organic cation transporters (25). 
Cholinergic activity is related to immune dysfunction and an up-regulation of cytokine 
production (25). Acetylcholine is also a major regulator of airway function by controlling 
contact between cells, stimulation of fluid secretion, ciliary beat frequency, and the 
overall regulation of the mucociliary clearance system (MCC), which are all major 
proponents of symptoms of CF disease (25). 
 
In addition to neurotransmitters, Schwann cells, and their effects on the peripheral 
nervous system, Sphingosine-1-phosphate (S1P) is a signaling pathway that occurs via 
the central nervous system and CFTR function aids in proper regulation of its expression 
(26). A 2012 study by Meissner et al shows an inverse relationship between 
microvascular CFTR activity and S1P signaling in vasomotor responses and myogenic 
tone (26). Sphingosine-1-phosphate is a signaling mediator that regulates artery tone and 
vasoconstriction, controlling blood flow, blood pressure, and transport of blood to the 
tissues (26). CFTR moves extracellular S1P across the plasma membrane for degradation, 
and if CFTR function is interrupted in any way, the S1P signaling will also be affected 
(26). During heart failure, S1P signaling is enhanced in the resistance arteries, and 
improper function of CFTR may be a reason for these conditions (26). The CFTR protein 
could act as an S1P transporter, limiting S1P receptor-mediated effects (26). CFTR 
dysfunction could cause conditions that are associated with S1P signaling (26). 
  
Immune Cells 
In addition to the role of the CFTR protein in the nervous system, defective CFTR also 
largely affects the body’s immune response. The body’s immune response can be divided 
into two different segments, the innate immune system and the adaptive immune system, 
as shown in Figure 4 (27). The innate immune system contains leukocytes that interact 
with the environment, in addition to opsonins and antimicrobials that lack memory (27). 
Innate immune cells have receptors for foreign molecules like the mannose receptor and 
formyl-peptide receptors that activate TLRs (27). The adaptive immune system includes 
B and T lymphocytes, both of which contain single antigen-specific receptors. Adaptive 
immune cells have antigenic memory that causes them to respond rapidly and in response 
to re-exposure to a foreign antigen (27). 
 
In a healthy person, alveolar macrophages are built for the innate immune response; in 
the lungs, they maintain a regulated, suppressive environment and prevent overreaction to 
antigens that enter the body (28). Macrophages work to clear pathogens by moving from 
protection to immunopathology by patrolling the airways (28). They produce cytokines 
and chemokines, kill and digest infected cells, and clear debris from the lung (28). 
However, their unique ability to produce a cytokine storm in response to bacterial or viral 
infections can lead to clogged airways, epithelial cell death, and unregulated repair of 
damaged tissue (28). Macrophages pose a problem for CF patients. Instead of producing 
inflammatory cytokines, alveolar macrophages produce IL-10 in CF lung disease; severe 




Since the CFTR protein alters function of immune cells, an abnormal immune response 
could cause CF patients to become more immunocompromised (29). Neutrophils provide 
the first line of defense against airway infection by killing and digesting phagocytized 
bacteria and fungi in the airways (30). CF airways contain an abundance of neutrophils, 
which can be attributed to the clearance of P. aeruginosa (31). Over time, the neutrophils 
fail to get rid of P. aeruginosa and the release of intracellular components becomes 
improperly regulated; this leads to development of bronchiectasis, or damage and 
scarring done to the airways (30). Neutrophilic dysfunction can be attributed to both the 
intense inflammation of the airways and to the lack of CFTR protein within the cell (30). 
A lack of CFTR function has been linked to decreased phagocytic capacity and in a 
cascade effect that results in lack of destruction of the P. aeruginosa bacteria, chronic 
infection, and accelerated injury to the site of infection (30).  Both mutation and 
inhibition of CFTR could cause neutrophils to produce more pro-inflammatory cytokines 
in response to the lipopolysaccharide (LPS) on the bacteria (31). CFTR reduces 
bactericidal ability in neutrophils of bronchoalveolar lavage cells, further exacerbating 
lung infection (32). 
 
The problem in CF patients is the quality of their immune response. In normal 
neutrophils, efficiency of microbicidal action requires the production of hypochlorous 
acid (HOCl); it is produced in the presence of hydrogen peroxide (H2O2) by an enzyme 
called myeloperoxidase (MPO) (33). The production of HOCl is necessary for proper 
host defense, especially since MPO-deficient humans and mice are likely to get fungal 
and bacterial infections (33). Neutrophils of CF patients have chloride-deficient 
phagosomes, causing them to lack the amount of necessary HOCl to kill an organism 
such as P. aeruginosa (33).  
 
Cystic fibrosis is a disease that leads to ineffective management of viruses and bacteria. 
The most common pathogen found in CF patients is Pseudomonas aeruginosa (P. 
aeruginosa), which produces a neutrophil-dominated host response that fails to clear the 
infection, causing a cycle of inflammation and infection to occur (34). A persistent 
inflammatory response contributes to progressive lung injury, and colonization of P. 
aeruginosa results in an antibody response, which unfortunately is not protective (34). 
Cell-mediated immunity against these bacteria is critical to host defense, and a subset of 
T helper cells called the T helper 17 (Th17) cells come into play (34). Th17 cells produce 
a cytokine called Interleukin-17 (IL-17), which causes the generation and recruitment of 
neutrophils to sites of infection (34). Murine models infected with acute pulmonary P. 
aeruginosa, Th17 plays a role in vaccine-induced protection; human models show that 
Th17 is in the submucosa of airways, and that IL-17 is produced from innate immune 
cells in the CF lung (34).  
 
In typical Th17 responses, IL-17 has been co-expressed with Interleukin-22 (IL-22), 
which is a cytokine that promotes repair of epithelial surfaces and elicits an anti-
microbial slate, thus becoming important for non-immune cells (34). IL-22 has been 
found to provide host defense upon inflammation of the gut following bacterial infection 
(34). T helper cells that produce IL-22 without IL-17 are called Th22 cells, which are 
 13 
found to infiltrate the skin in inflammatory disorders such as psoriasis while also 
releasing antimicrobial peptides; Th22 cells are strong elements in host defense against 
lung pathogens such as Klebsiella pneumoniae (34). A 2014 study by Bayes et al shows 
that the presence of Th22, Th17, and Th1 memory CD4+ cells in CF patients are 
important for the host defense by the immune system in CF patients (34).  
 
In addition to IL-22 and IL-17, Interleukin-13 (IL-13) is also important in inflammatory 
responses, specifically in intestinal regulation (35). IL-13 has effects on hematopoietic 
and non-hematopoietic cells, such as macrophages, epithelial cells, and enteric neurons, 
while also mediating smooth muscle contraction, and regulating intestinal epithelial 
differentiation and apoptosis (35). IL-13 is an important factor in regulating the intestinal 
epithelium and more relevantly, CFTR-mediated chloride ion conductance (35). IL-13-
induced chloride secretion is CFTR-dependent and is associated with increased 
expression of CFTR (35). 
 
The airways of those affected by CF fail to manage bacteria efficiently, causing infection 
(32). Two cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), are 
released upon response to P. aeruginosa infection and are released in higher amounts in 
Cystic Fibrosis airways (36). IL-1β and TNF-α and stimulate fluid secretion by 
submucosal glands that can be blocked by the CFTR inhibitor (36). A 2012 study by 
Baniak et al in swine airway submucosal glands shows that IL-1β stimulates CFTR-
mediated chloride movement across submucosal gland serous cells (36). Bacteria-
triggered gland secretion occurs as part of the normal innate immune response to 
bacterial inhalation (36).  
 
The role of CFTR in non-epithelial cells has somehow received less attention, but it has 
been established that the absence of CFTR in lymphocytes leads to a divergence in the 
adaptive immune response in living cells (29). CFTR expression in lymphocytes is 
associated with volume regulation and regulation of CD8+ T cells, which are cytotoxic T 
cells that make cytokines (29). In addition, a defect in cyclic AMP-dependent chloride 
currents in CF-derived lymphocytes shows evidence of the role of CFTR in lymphocytes 
(33). Studies also show that regardless of B cell function in Cystic Fibrosis patients, the T 
cell activation events and helper function provide a strong antibody response (29). By 
testing small molecule regulators of the immune response, researchers can use these 
findings to help CF patients (29). 
 
In a 2011 study by Abu-El-Haija et al, an analysis of the abundance of neutrophils and 
macrophages in healthy versus diseased pig pancreatic blood was completed by 
comparing CD14 antigen levels in the blood (37).4 Overall, the CF pig pancreas exhibited 
a significantly increased level of monocytes, macrophages and neutrophils than non-CF 
pigs and it is even more striking that neutrophils were almost nonexistent in the non-CF 
pig pancreas (37). The innate immune system response proves to be exclusive in the CF 
pig pancreas, as macrophages and neutrophils both infiltrated the pancreas, signaling 
pancreatitis (37). The same study shows that T helper cells and B cells were found in 
                                                 
4CD-cluster of differentiation; CD14 detects LPS wall of bacteria 
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higher numbers in the pancreas of CF pigs versus non-CF pigs (37). It can be concluded 
that there was indeed activation of adaptive immune system cells (B and T cells) in the 
pancreas of newborn CF pigs (37).  
 
In summary, macrophages express CFTR and their defect by contributing to an 
inappropriate host response to opportunistic bacterial pathogens; this response consists of 
to chronic inflammation and remodeling of the site of inflammation (38). Bacteria target 
neutrophils, and this causes apoptosis or programmed cell death, in addition to a massive 
release of toxins and pro-inflammatory products (38). Neutrophils end up doing more 
damage than good to the airways due to their domination in the inflammatory response 
(38). T helper cells recruit cytokines to the scene in order to promote this inflammatory 
response (34). The unique presence of both innate and adaptive systems in order to 
combat CF shows the extensiveness and complexity of the disease (37). 
 
The Relevance of Animal Models  
Animal models have been used to study the effects of CF on live organisms and to come 
to more clear conclusions about the disease. The following animal models show the 
effects of CF on target areas of the body including the gastrointestinal tract, pancreas, 
liver, and gall bladder. A 2011 study by Keiser and Engelhardt shows similarities 
between phenotypic effects of CF on animals and humans.  
 
Gastrointestinal (GI) Tract 
Pigs and ferrets with CF show a phenotype of a condition called meconium ileus, an in-
utero intestinal obstruction present in about 15% of newborn infants with CF, when the 
earliest stool of an infant becomes blocked in the ileum of the small intestine (39). 
Meconium ileus is fatal within the first 48 hours after birth in piglets with the 
dysfunctional CFTR gene if no surgery is performed, and is similar to what is exhibited 
in the phenotype of infants with cystic fibrosis (39). Intestinal atresias, diverticulosis, and 
microcolon are all conditions that occur in CF infants that can be seen in pigs and ferrets 
that have the dysfunctional gene as well (39). Meconium ileus in the cystic fibrosis ferret 
has been found to have a significant genetic influence, as also observed in infants with 
CF (39). The pig with the CFTR-F508del protein exhibits residual processing to the 
plasma membrane and partial function, demonstrating that the pig likely has high levels 
of functional CFTR in the intestine to clear meconium after birth (39). Unlike the CF 
ferret or pig, the CFTR knockout rat does not present with meconium ileus at birth (40). 
Animals develop intestinal blockage only after weaning off their mother’s milk and 
nutrients, which is similar to intestinal obstruction syndrome observed in children and 
adults with the disease of CF (40). 
 
Pancreas 
In addition to the gastrointestinal tract, the pancreas is a severely affected organ in people 
with CF (39). In newborn pigs with the knockout CFTR gene, the destruction of the 
exocrine pancreas compares to more severe cases, while the pigs with the mutated 
F508del mutation have a less severe exocrine pancreatic phenotype than the one with the 
lack of the gene (39). Dysfunctional protein could actually reduce the force of the disease 
progression (39). In ferrets with CF, the exocrine pancreas undergoes destruction over the 
 15 
course of the first few months of life, leading to pancreatic dysfunction and a need for 
pancreatic enzymes (39). Both pig and ferret models demonstrate the decline of the 
exocrine pancreas in patients with CF.  
 
Liver and Gall Bladder 
In addition to pancreatic and GI tract problems, CF also affects the liver and gallbladder 
(39). Biliary cirrhosis is a common cause of morbidity in humans with CF; pig and ferret 
models have been studied to explore hepatic lesions, cellular inflammation, and fibrosis, 
which are all major signs of biliary cirrhosis (39). Newborn ferrets with CF have 
unusually high levels of bilirubin and plasma alanine aminotransferase, both of which are 
indicative of liver disease, and this finding is similar to children with CF who have 
unusually elevated liver enzymes in their blood (39). In addition to the liver, gallbladder 
disease is observed in 15-30% of older CF patients during the autopsy (39). This disease 
is extremely severe in pigs with the CFTR-F508del protein (39). In the gall bladder of 
affected pigs, aggregation of neutrophils, mononuclear inflammation, and luminal 
obstruction by bile and mucus have all been found (39). 
 
Growth and Nutrition 
Nutritional defects are also seen in people with CF (39). It has been found that chloride 
secretion is defective in the thyroids of pigs without the CFTR gene, possibly 
demonstrating a mechanism for CF-linked hypothyroidism (39). The serum of newborn 
pigs and infants with CF show reduced levels of the hormone called insulin-like growth 
factor 1 (IGF-1), and mice with CF have similar reductions in this serum IGF-1 when 
they grow older (39). CFTR plays a role in the neuroendocrine system in controlling 
growth (39).  
 
Transcriptional Regulation  
DNA must be properly transcribed into mRNA and then translated into protein (40). 
Histone acetylation and deacetylation occur within the coding regions of genes, either 
adding or removing acetyl groups from histones (40). Histone acetylation and 
deacetylation are two critical processes for proper gene expression and proper cellular 
function, and they must be balanced for correct protein function (40). A 2011 study by 
Gunderson et al provides evidence that histone acetylation and deacetylation maintain 
proper co-transcriptional splicing by facilitating dynamic rearrangements of the 
spliceosome, which are ATP-dependent (40). There is an increase in histone acetylation 
due to lack of histone deacetylases (HDACs), resulting in altered spliceosome dynamics 
(40). Methylation is another type of histone modification that creates binding sites for 
factors that help with splicing, and therefore improve transcriptional modifications (40). 
Both methylation and acetylation are stable modificiations, but acetylation could allow 
more dynamic rearrangements of the spliceosome (40). 
 
Multiple HDACs can remove acetyl groups in a process known as histone deacetylation 
(40). Deacetylation decreases gene expression, while acetylation increases gene 
expression (40). Although HDACs work in transcriptional regulation, studies have shown 
that inhibiting these HDACs could be more productive than allowing them to work (41). 
A 2011 study by Hutt et al shows that cyclic tetrapeptides restore CFTR activity by 
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inhibiting HDACs. Cyclic tetrapeptides also correct the most common mutation, F508del, 
from the ER so that cell surface channel activity can be enriched once again and the 
smooth influx and efflux of chloride can resume (41). These cyclic tetrapeptides were 
shown to overcome the trafficking defect associated with the F508del protein, which was 
monitored on its way to the cell’s surface by Western blot analysis (41, 42).5 Therefore, 
protein acetylation pathways can actually work in correcting the maturation of the folding 
and function of this mutation (41). The connection between HDAC inhibition and CF 
biology can not only help with CF, but could also help to potentially correct other 
protein-misfolding diseases (41).  
 
Other transcription factors, such as Liver X receptors (LXRs) may contribute to CF. 
These are transcription factors that regulate lipids and glucose metabolism and belong to 
a family of nuclear receptors (42). LXRs have been found to regulate the function of 
several important transport systems in the body such as the epithelial sodium channel, 
kidney transporters, organic anion transporters, and the sodium-inorganic phosphate co-
transporter (42). A 2013 study by Raksaseri et al provides evidence that these LXRs are 
capable of reducing CFTR-mediated chloride secretion in a cell line in murine primary 
inner medullary collecting duct cells (42). Results of the Western blot analysis show an 
inhibition of chloride secretion due to a decrease in CFTR protein, and this is 
independent of down-regulation of its mRNA expression (42). LXRs, or transcription 
factors, are able to down-regulate the CFTR-mediated chloride secretion of kidney cells 
(42). 
 
Another transcription factor, called the glucocorticoid receptor (GR), acts as a repressor 
of CFTR expression (5). Yigit et al conducted a study in 2013 that tested the binding of 
GR in nucleosome-depleted regions in a specific cell type (5). If ligand activation of GR 
down-regulates CFTR expression, then ligand-receptor binding inhibition could cause an 
increase in CFTR expression in cells, resuming proper conductance of ions into and out 
of cells (5). 
 
Bacterial infections are more likely to occur in patients with CF due to mucus 
dehydration and reduction in mucociliary clearance (43). One such infection is gram-
negative P. aeruginosa, as it is a cause of pulmonary inflammation in lung disease of 
Cystic Fibrosis patients and correlates with a faster decline in lung function, morbidity, 
and mortality (43). The innate system responds to the cycle of infection and inflammation 
through Toll-like receptors (TLRs), which then trigger signaling cascades by 
transcription factors such as NF-κB (43). Upon P. aeruginosa infection, TLRs are 
stimulated and activate the Extracellular-signal Regulated Kinase (ERK1/ERK2 
pathway), which regulates cell growth and differentiation, and is used for inflammatory 
signal transduction (44). 
 
In order for the inflammatory response to be timely and for regulated termination of 
signaling to happen, intracellular membrane trafficking and routing must occur in the 
receptor-ligand complex (43). Once infected with Pseudomonas aeruginosa bacteria, the 
                                                 
5Western blot analysis-an experimental procedure used to detect histone modifications 
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detection of the LPS bacterial wall causes TLR4 activation to occur by dimerization (43). 
The TLR4-LPS bound complex is then internalized, and TLR-induced inflammatory 
signaling is inhibited once the complex is targeted for degradation (43). This complex is 
then directed toward endosomes for degradation or toward the Golgi apparatus for 
recycling (43). The functional CFTR protein works in altering the internal 
compartmentalization of TLR4 in macrophages, but patients with CF often show signs of 
ongoing and uncontrolled inflammation (43). Altered TLR4 expression in CF airway 
cells actually contributes to an increased inflammatory response (43). Patients with CF 
show chronic uncontrolled activation of NF-κB and an increased amount of released 
inflammatory mediators than the healthy population does (43).  
 
The airway epithelium is important because it is the first line of defense for the lungs 
(35). Immune cells act as a mechanical barrier to reduce the risk of infection and to also 
produce chemokines and cytokines that recruit phagocytic cells to ingest organisms and 
infected cells (35). Due to the sterility of the lungs, interactions with microorganisms can 
cause inflammation as a response to infection (35).  The immune system essentially gains 
access to bacterial information by the shedding of surface or intracellular receptors, 
known as pathogen-associated molecular patterns (PAMPs) (35).  When the innate 
immune system senses these PAMPs, such as the LPS or flagella, inflammation is 
stimulated (35). In addition to this inflammatory response, the mucosal response is used 
for clearance of pathogens (35). Excessive inflammation represents an 
immunocompromised respiratory system, making the regulation of pro-inflammatory 
signaling so important for the body’s cells (35). Components of the innate immune 
system, such as NF-κB, are activated in order to regulate signaling (35). TLRs are 
integral membrane glycoproteins that recognize microorganisms, and they sense 
microbial products or PAMPs, eventually leading to NF-κB expression (35). In CF 
patients, the lungs are usually in a hyper-inflammatory state, which causes the signaling 
of NF-κB (35). 
 
Post-Translational Modifications 
Success in ER folding and assembly is essential for proteins to exit the ER, and a large 
fraction of translated proteins fails at the quality control checkpoints that follow (7). Due 
to this failure, these proteins are retained at ER checkpoints, leading to ubiquitylation and 
degradation by a proteasome, called 26S, which is a protein complex that breaks down 
other proteins (7). Ubiquitylation is a post-translational modification, or an addition to a 
protein after it has been made (7). The CFTR protein does not always get ubiquitylated 
because it is long and difficult to fold (7). A 2013 study by Ahner et al showed that ER-
based machinery containing heat shock proteins facilitated CFTR folding (7). A reduction 
in the NBD1 aggregation occurred upon interaction with one of the heat shock proteins, 
and the CFTR folding efficiency improved (7). 
 
Modifier Genes 
TGF-β is a genetic modifier of CF, which mediates the pulmonary fibrosis that 
characterizes respiratory deterioration in patients with CF (12). It has been shown that CF 
patients with specific polymorphisms in TGF-β1, a pro-fibrotic cytokine, are at a higher 
risk for severe lung disease (45). Multi-organ fibrosis is known to occur in cystic fibrosis 
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of the pancreas with conditions such as liver cirrhosis, pancreatic fibrotic obliteration, 
and vas deferens obstruction (45). TGF-β mediates fibroblast physiology in the lungs and 
also contributes to the severity of the disease in patients with CF (46). A myofibroblast is 
a fibroblast containing smooth muscle, and it has been previously identified as a main 
mediator of profibrotic conditions (45). Myofibroblast differentiation usually occurs due 
to tissue injury or mechanical stimulation, and contributes to healing of wound edges, 
while still promoting the formation of extracellular matrices (45). In a healthy person, 
when tissue injury is resolved, myofibroblasts undergo apoptosis, or programmed cell 
death, but in CF patients there has been an increase in myofibroblasts in alveolar tissue 
(45).  
 
The myofibroblast phenotype depends on TGF-β and occurs due to epithelial injury or 
inflammation, which are two main characteristics of CF respiratory deterioration (45). 
TGF-β must be activated to bind the TGF-β receptor complex, which then transmits a 
signal through Smad protein phosphorylation (pSmad2/pSmad3) (45). Myofibroblast 
differentiation is induced with the presence of TGF-β and mechanical strain (45). TGF-β 
signal transduction occurs due to hypoxia, epithelial injury, and an increase in protease 
activity (45). In addition to the induction of the expression of genes that promote fibrosis, 
TGF-β1 is secreted by endothelial, hematopoietic, and connective tissue cells, and 
inhibits epithelial proliferation (45). Myofibroblasts also promote TGF-β activation by 
contracting, and through mucus-plugging and chronic cough in CF (45). As this modifier 
signals for the myofibroblast phenotype in the CF lungs, it could provide insight into the 
necessity for anti-fibrotic therapies, which could decrease tissue scarring and respiratory 
compromise in CF patients (45).  
 
Pulmonary fibrosis is a common end-stage of CF lung disease, and tissue remodeling of 
the airways occurs by increased collagen deposition (47). Fibroblasts form cells that 
produce an extracellular matrix that regulates tissue repair in parenchymal tissue (47). 
They can secrete strong inflammatory chemoattractants such as chemokines, monocytes, 
and interleukins, contributing to disease pathogenesis (47). In particular, fibroblast 
dysfunctions are seen in CF patients and they have a phenotype with increased 
proliferation and myofibroblast differentiation; dysfunctional fibroblasts are a potential 
target for treatment of CF patients (47). 
 
In addition to TGF-β, other genes have been found that can be grouped as modifier genes 
that contribute to phenotypic differences observed in diseases like CF (48). Mannose-
binding lectin (MBL) is a serum protein that is produced by the liver and may have an 
effect on disease severity in CF patients (49). It binds to bacteria, activating the lectin 
pathway of complement, and causing direct lysis of the target (49). The lectin pathway is 
antibody-independent and is triggered by MBL binding to carbohydrates on the surface of 
microorganisms (49). MBL also causes phagocytosis by bridging phagocytes and 
microorganisms such as P. aeruginosa and Staphylococcus aureus (49). MBL 
accumulates in large quantities in the lungs during acute inflammation in patients with 
CF, thus promoting phagocytosis and complement system activation (49). Lack of MBL 
has been associated with reduced lung function, earlier infection with P. aeruginosa, and 
a higher rate of the end stages of CF (49). 
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The mannose-binding lectin (MBL2) gene encodes a protein, which is secreted by the 
liver and leads to opsonization and activation of the complement system through the 
classical pathway (48). This serum concentration of the protein and MBL’s ability to 
trigger the complement system depends on single-base mutations in the MBL2 gene (48). 
These mutations may increase the susceptibility of carriers to colonization by bacteria 
and viruses. The IL-8 gene codes for a member of the chemokine family and responds in 
cases of acute inflammatory reactions (48). IL-8 is produced by monocytes, 
macrophages, and fibroblasts, and helps in activation and movement of neutrophils from 
the blood to the tissues for an amplification of an inflammatory response (48).  
 
Some genes and gene modifiers play a role in inflammation, such as the tumor necrosis 
factor alpha (TNFα) gene and Alpha-1-antitrypsin (AAT) (48, 49). TNFα leads to the 
expression of a pro-inflammatory cytokine that responds to specific triggers; the cytokine 
stimulates a release of IL-6 and IL-8 cytokines that cause an increase in mucus 
production (48, 49). AAT, another modifier gene, codes for a serine protease 
glycoprotein; the glycoprotein limits the amount of tissue self-damage during an 
inflammatory response. Severe AAT deficiency results in a pulmonary disorder that is 
similar to emphysema (48).  
 
In contrast to TNFα,  peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-
controlled transcription factor of the nuclear receptor family that has an anti-
inflammatory role in regulating gene expression by transactivation or transrepression 
(50). In the lungs, PPARγ has been proven to go beyond the regulatory role of anti-
inflammation and extends to host defense (50). Results of a 2012 study by Griffin et al 
provide a strong inverse correlation between PPARγ expression and to a lower extent 
PON2 gene expression with neutrophil counts; low levels of these two genes are 
associated with high levels of inflammation (51). This specific study shows the genes in 
BALF cells associated with P. aeruginosa infection only, meaning that this pathogen is 
so resistant that PPARγ and PON2 could actually be therapeutic if used in an inverse 
manner (51). If it holds true that less gene expression causes more inflammation, a drug 
that inhibits PPARγ could protect against the infection and inflammation cycle of P. 
aeruginosa (51). PPARγ signals for the cessation of neutrophils and macrophages and 
assists in inflammation resolution, thus ending the cycle of infection and inflammation in 
diseases, and proving to be a therapeutic target (50). 
 
Genome-wide Association Studies  
In light of the high cost and lack of feasibility of genome sequencing, genome-wide 
association studies (GWAS) have become more practical and provide ways to study large 
populations without bias of pre-existing models (52). Scientific research has more 
freedom to identify new genes, regulatory sequences, and new pathways (52). 
Understanding the ways in which genes and their alleles exert their effects can lead to 
new therapeutic approaches (52). GWAS use genetic profiles geared towards 
personalized medicine (52). For example, two people with different inflammatory 
responses could need two different dosages of anti-inflammatory drugs; while these may 
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be common treatments, each could be more beneficial with the help of modifier genes 
(52). 
 
Since Cystic Fibrosis is a rare genetic disorder that is caused by several genetic variants 
within a single gene, and due to the strength of these variants, the disease follows an 
autosomal recessive inheritance pattern in families who have the disorder (53). In a 2012 
study by Bush and Moore, multiple mutations were found in the CFTR gene as the cause 
of CF (53). Families affected by CF were genotyped using a collection of genetic markers 
across the genome; markers that diverged in families were examined (53). The technique 
used to trace these mutations is called linkage analysis, and it is only applied to rare 
disorders such as CF (55). Linkage analysis does not work well for diseases that have 
more common disorders such as cancer or heart disease, showing that genetic 
mechanisms strongly differ among rare diseases (53).  
 
A 2013 study by Weiler and Drumm provides evidence of two new genes associated with 
CF, called APIP and EHF (52). APIP encodes the Apaf-1-interacting protein, and EHF is 
an epithelial-specific transcription factor; both act as disease modifiers through different 
models (52). It is hypothesized that APIP prolongs neutrophilic inflammation and leads 
to more severe lung disease, while EHF regulates epithelial cell differentiation during 
times of stress and inflammation (52). 
 
Variability in CF phenotypes is partially due to non-CFTR genetic modifiers. Mucin 
genes participate in the development of the lung disease and can be seen as genetic 
modifiers of the CF phenotype (54). Mucins are expressed as glycoproteins that are 
important in the airway epithelium (54). Mucins contain a tandem repeat (TR) domain 
that shows variation in repeat number, also known as variable number tandem repeats 
(VNTRs) (54).  Differences in VNTR sizes could cause a change in mucin protein 
molecular weight by two-fold (54). These secreted mucins are responsible for 
mucociliary clearance and contribute to glycocalyx barrier functionality (54). Cystic 
fibrosis, being a respiratory disease, has variations in mucin expression that could 
contribute to pathophysiology, thus leading to less mucociliary clearance, dehydration of 
the ASL, and increased risk of chronic lung conditions (54). Since at least 50% of the 
variability in the severity of the lung disease of CF patients is attributed to heredity, 
genetic modifiers of CF must explain some of this heritable variation (54). Phenotypic 
changes due to respiratory mucins could add to genetic modification, especially VNTR 
length (54).  
 
A 2013 genome-wide association study by Blackman et al was conducted using 3,059 
individuals with CF and 644 of them having CF-related diabetes (55). Cystic fibrosis-
related diabetes (CFRD) is a common complication of cystic fibrosis associated with 
severe lung disease, malnutrition, and death (55).  CFRD is age-dependent, affecting 19% 
of adolescents and 40-50% of adults with cystic fibrosis, and is strongly influenced by 
modifier genes (55). In addition, Single-Nucleotide Polymorphisms were found that were 
associated with the SLC26A9 gene, an epithelial chloride and bicarbonate channel, which 
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interacts with the CFTR protein (55). 6 Since diabetes is an extremely prevalent 
complication of CF, susceptibility can be determined by variants associated with 
SLC26A9 at four gene loci (55). These gene variants (TCF7L2, CDKAL1, CDKN2A/B, 
and IGF2BP1) are associated with both Type 2 diabetes and CFRD (55). These loci 
contribute to both diseases and support the concept that diabetes develops in individuals 
who may have underlying susceptibility to pancreatic β-cell dysfunction (55). Variants in 
CDKAL1 have been reported to damage pro-insulin translation and to stimulate the ER 
stress response that contributes to apoptosis, or programmed cell death (55). CDKAL1 
works as a CFRD modifier because ER stress is stimulated by CFTR mis-folding (55). 
TCF7L2 may affect β-cell mass and pro-insulin processing, and CDKN2A/B suggests a 
role for growth, apoptosis, and insulin processing in CFRD (55). This study shows that 
even though CFRD is not the same disease as Type 2 diabetes, they share genetics which 
cause similar disease pathways, also showing how CF affects the pancreas just as much 
as other organs (55). 
 
The pancreas has as an endocrine function, which is to synthesize hormones such as 
insulin from beta cells, glucagon from alpha cells, and somatostatin from delta cells (56). 
It also has exocrine functions, which are to secrete digestive enzymes into the small 
intestine and to produce pancreatic polypeptide (PP) producing cells in the pancreas (56). 
Results of a 2013 study by Zertal-Zidani et al show that a small molecule inhibitor called 
glibenclamide triggered the endocrine differentiation pathway in the developing pancreas, 
increasing the number of endocrine cells (56). This study concluded that inhibition of 
CFTR increases the number of endocrine cells in the developing pancreas, and that these 
small molecule inhibitors can amplify the development of pancreatic endocrine cells (56). 
The mechanism in which CFTR inhibition increases the number of pancreatic endocrine 
cells is unknown; however CFTR functions as a chloride channel activated by cyclic 
AMP and protein kinase, and facilitates the transport of organic ions (56). There is 
definitely evidence of its regulation of ion channels, pH, and cell volume (56).  
 
In addition to its effects on the pancreas, Cystic Fibrosis is also linked to bone disease. 
CF-related bone disease occurs due to low bone mass and increased fracture risk as a 
result of complications of CF (57). Damage to osteoblast bone formation and increased 
osteoclast bone resorption both occur, in a process known as “uncoupling bone turnover.” 
Vitamin D deficiency, inflammatory cytokines, and intestinal malabsorption all 
contribute to this bone disease (57). A direct link is shown between dysfunctional CFTR 
and Cystic Fibrosis-related bone disease, especially via the inactivation of the CFTR gene 
in osteoblasts and its contribution to low bone mass (57). In a 2013 study by Stalvey et al 
focusing on murine bone, CFTR was expressed in osteoblasts (57). Inactivation resulted 
in defective differentiation and late new bone formation, and CFTR inactivation also 
resulted in pancreatic disease (57). As CF patients age, they tend to have age-related 
complications such as spinal, arm, and hip fractures, and these findings show that CFTR 
expression in the bone causes reduced osteoblast differentiation and enhances osteoclast 
bone resorption (57).  
                                                 
6SNP: Single-Nucleotide Polymorphism, or a DNA sequence variation occurring when a single nucleotide 
(A, T, C, or G) in the genome differs between members of a biological species or paired chromosomes; ex: 
DNA fragments from different individuals could be AAGCCTA to AAGCTTA  
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Not only do genes affect the observed phenotype in CF patients, but environmental 
factors play a role as well (58). A 2012 twin study by Blackman et al underscores the 
influence of genetic and non-genetic factors on nutrition in young CF patients who 
experience the greatest changes in growth rates (58). BMI, or body mass index, (kg/m2) 
was used as a marker of nutritional status and more accurately predicts the nutritional 
failure in CF patients than other conventional measures (58). Nutritional status of young 
twins and siblings with CF was analyzed, and genes other than CFTR were found to 
influence the variation in body mass index, such as genetic modifiers located at the loci 
of chromosomes 1 and 5 (58). CF patients are under nutritional stress due to poor appetite 
and weight loss; this lack of nutrition could make patients uniquely sensitive to genetic 
factors, which also affect maintenance of weight (58).  
 
Another twin study from 2011 by Stanke et al suggests that both inherited and 
environmental factors influence CF disease manifestation (59). The shared prenatal and 
early postnatal period distinguished twins from siblings, and was associated with low 
differences within the twin pair itself in weight-for-height percentages (59). In addition, 
concordance in lung function was dominated by genetic factors, as only monozygous 
twins shared their entire genetic information, in contrast to dizygous twins, or siblings 
who only share half of their genetic information (60). Inherited factors have a larger 
impact on patient-to-patient variability in weight-for-height percentages than for lung 
function (59).  
 
Current and Potential Therapies for CF 
CFTR governs a dominant fluid and electrolyte secretory pathway in the nasal airways, 
essentially regulating mucociliary clearance (MCC) in airway epithelia (61). This 
mucociliary clearance is so important for maintaining healthy sinus mucosa because it 
contains vital elements for function, such as ASL (61). There must be a balance of ion 
transport across epithelial cell membranes in order to maintain adequate viscosity and 
depth in this ASL (61). The CFTR channel transports a high amount of chloride and 
bicarbonate to the lower and upper respiratory epithelium (61). If the chloride transport is 
disrupted, this could lead to dehydrated ASL and mucus blockage, which is a common 
occurrence for patients with CF (61). Mucus stasis is shown in people with chronic rhino 
sinusitis, a condition in which the sinuses surrounding the nasal passages become 
inflamed or swollen (61). This interferes with drainage and causes mucus to buildup (61). 
Results from a 2013 study by Zhang et al show that there are certain potentiators, one 
known as Resveratrol, that cause the CFTR channel to have a higher open probability, 
thus regulating the mucociliary pathway (61). By changing the CFTR protein itself, the 
normal governance of the channel could prevent mucus blockage in the sinuses (61). 
 
In people with dysfunctional CFTR or lack of CFTR protein, CFTR regulation can be 
targeted by drugs that act at a site outside the cell on the CFTR protein; these drugs 
decrease the function of voltage-dependent blockers or anions, and therefore increase 
overall CFTR function in CF patients (9). There are currently potentiatiors, or drugs that 
enhance the function of the defective CFTR protein channel. CF-causing mutations 
involved in ATP-dependent gating can be corrected by small molecules, which indirectly 
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change the channel gate via allosteric binding (62). A 2012 study by Eckford et al shows 
the use of a drug called VX-770, also known as ivacaftor or kalydeco, which causes the 
defective channel to open via a different mechanism, not involving ATP binding and 
hydrolysis (62). VX-770 is a small molecule that causes ATP-independent 
phosphorylation of CFTR to occur (62). VX-770 binds directly to phosphorylated CFTR 
and opens the channel without ATP (62). VX-770 may help patients with mutations that 
especially cause disruption to the site of the CFTR protein that ATP would normally bind 
to during ATP-dependent phosphorylation (62).  
 
Increasing activity of the CFTR protein could potentially treat CF. A 2011 study by 
Ramsey et al shows a randomized, placebo-controlled trial in which VX-770 was 
associated with significant improvements in primary and secondary end points in people 
with CF who had at least one copy of the G551D-CFTR mutation (63). VX-770 is a 
systemic modulator that could affect CFTR function in GI epithelia, contributing to 
improved absorption of nutrients in patients with CF; after 48 weeks, patients treated with 
VX-770 had gained an average of 2.7 kg more weight than those receiving the placebo 
(63). Patients receiving VX-770 were 55% less likely to have a pulmonary exacerbation 
than those receiving the placebo over a period of 48 weeks (63). VX-770 was the first 
agent to show reduced sweat chloride levels, and it also improved CFTR-mediated ion 
transport (63). Ramsey’s study shows that there are drugs that target CFTR dysfunction, 
leading to the change in phenotype, and that the CFTR protein is a valid therapeutic 
target for the pathophysiology of CF (63).  
 
Mutant CFTR proteins can be studied in a cell-free system where protein interactions are 
minimized and ligand concentrations are well controlled (62). The VX-potentiation effect 
is mediated via specific binding to the CFTR protein (62). Future work could determine 
whether VX-770 may indirectly change the properties of the phospholipid bilayer (62). 
There are advantages to allosteric binding rather than directly targeting the active site, 
such as having a greater potential for selectivity and also conserving ATP-binding sites 
across members of the ABC family of membrane proteins (62). A compound that targets 
these active sites, such as VX-770, may have cross-reactivity with different family 
members (62). VX-770 works by interacting with a region unique to CFTR and away 
from the catalytic site (62). Since it works without ATP, when VX-770 binds with ATP, 
an additive effect occurs that stabilizes open conformation and enhances the probability 
of opening the channel (62). Essentially, the mechanism of action is to target the defect of 
the mutation in the CFTR channel (62). By using purified and reconstituted CFTR and 
mutated CFTR proteins, greater precision occurs in targeting the actual pore (62).  
 
VX-770 is also used as a single agent in combination with correctors to target a broad 
range of mutations (64). The G551D-CFTR mutation is currently targeting CF in its third 
phase trial in 2-5 year olds (64). Data is expected in approximately 300 children in North 
America, Europe, and Australia (64). A 2013 Phase 3 study of VX-770 was completed on 
patients with R117H mutation, which is a residual and mild form of the CF phenotype; 
results indicate an increase in lung function in patients who took the VX-770 drug as 
opposed to patients who took the placebo (64, 66). A Phase 2 clinical study of Ivacaftor 
in people with residual function mutations other than R117H is being conducted by 
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Vertex Pharmaceuticals (64). Enrollment for this study is complete and data should be 
expected in the summer of 2014 (64). Vertex is preparing to conduct a 12-week study of 
a potentiator called VX-661 in combination with Ivacaftor in people with CF who have 
two copies of the F508del mutation, and enrollment in this trial will occur in the spring of 
2014 (64). Ataluren aims to correct the underlying genetic defect in people with Class I 
nonsense mutations of CF; a phase 3 trial will occur, having proven to work better 
without tobramycin, a chronic aminoglycoside antibiotic (64). Lynovex is a drug that 
treats persistent lung infection in people with CF (64). It uses a new peptide-based 
approach that breaks down excessive mucus, penetrates, and kills bacteria in a way that 
prevents them from establishing antibiotic-resistant infections. Trials will begin and end 
with results in 2014 (64). CF Matters is a collaboration project that aims to develop 
personalized antibiotic treatments for CF chest infections, led by Professor Stuart Elborn, 
Director of Queen’s Centre for Infection and Immunity (64). This study will contain 252 
patients from 7 countries and will use molecular next generation DNA sequencing 
methods to detect all the bacteria present in the sputum of CF patients; therefore the study 
will determine what antibiotics to use in individual patients (64). This precision in 
determination of bacteria in the sputum will occur in order to avoid antibiotic resistance 
(64).  
 
In contrast to therapies that open the CFTR channels, there are some therapies that block 
the opening of this same channel. Open channel blockers are used to block the CFTR 
channel from influx and efflux of chloride channels in cells of the body, thus inhibiting 
CFTR from functioning if the current function is overactive. These blockers work by 
binding to specific sites within the channel pore with high affinity (60). Open channel 
blockers are anions, and positively charged amino acid side chains in the CFTR channel 
pore help with electrostatic attraction of chloride ions (60). Mutations that eliminate the 
positive charge on the lysine side chain significantly reduce the channel blocking affinity 
of open channel blockers, such as glibenclamide (60). These open channel blockers all 
have different structures, but they share a common blocking mechanism: they are 
attracted into the pore by electrostatic attraction between the negative charge on the 
blocker and the positive charge on the lysine side chain (60). Once inside the pore, they 
bind tightly enough to block the opening and prevent chloride from leaving (60). The 
positive charge on the lysine side chain explains the sensitivity of CFTR to anion 
blockers because a positive charge is necessary to attract chloride ions and maximize the 
rate of conductance (60). This fixed positive charge also attracts all anions in the 
cytoplasm, which stay within the vestibule long enough to block the chloride ion passage 
into the pore region (60). Because the channel usually secretes chloride and bicarbonate 
at hyperpolarized membrane potentials, the channel contains this fixed positive charge to 
bind to these anions from the cytoplasm via electrostatic attraction (60). This positive 
charge ensures efficient attraction of monovalent anions, but beyond this point, anions 
can pass into a narrow uncharged pore region that acts as a size selective filter to stop 
larger organic anions from leaving the cell. The pore region probably inhibits anions that 
are attracted to the positive charge of the lysine side chain but that are too large to pass 
into the narrow pore region (60). These blocking anions are voltage-dependent; open 
channel blockers could potentially inhibit CFTR function in people who have unusually 
elevated levels of CFTR in their body’s cells (60).  
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Sodium channel blockers inhibit the sodium channel and improve hydration of airway 
surfaces, therefore countering defective CFTR (65). Loop diuretics are used to inhibit the 
CFTR channel (65). When added to intracellular solution, loop diuretics inhibit CFTR 
chloride currents with potency approaching that of small molecule inhibitors such as 
glibenclamide; these inhibitors have structural similarity to loop diuretics (65).  
 
Significance 
Even with various phenotypic manifestations depending on the area of the body, the 
defective CFTR protein itself must be targeted in order to treat the Cystic Fibrosis 
disease. In order to increase or decrease the balance of ions in and out of the cells of the 
body, the channel pore can be opened or blocked, which could potentially provide many 
avenues for future drugs and research. These current drugs are being administered along 
with therapies in order to find ways to eliminate phenotypic manifestations via the CFTR 
channel, which is the main defect causing CF. This one channel in the cell affects the 
whole body, and this realization is a milestone. 
 
Conclusion 
In conclusion, cystic fibrosis is a disease that has wide phenotypic variability. It has been 
proven that mutations in the CFTR gene are the underlying cause of the defect that results 
in CF. Five classes of mutations were found to be the main causes of the defective CFTR 
gene that causes CF, some being more common mutations than others. Studies 
underscore the lack of CFTR protein and its cause of an imbalance of chloride and 
sodium conductance in the channel. An imbalance of water and salt in regions of the 
body cause mucus buildup and airway blockage. Animal models show the manifestation 
of the disease in areas of the body such as the pancreas and gastrointestinal tract, 
representing an elevated immune response from the blood of these areas of the body. 
These studies show the complexity of CF in the body’s need for both adaptive and innate 
immune system responses. Transcriptional regulation and post-translational modifications 
were studied in order to retrace the steps of the CFTR protein processing and to show that 
the dysfunction of the gene occurs as early as the conversion from gene to protein, and 
that there are ways to correct for this or cause it by targeting these stages. Gene modifiers 
have been found to both aid and inhibit the effects of defective CFTR gene function, 
providing substantial evidence that the CFTR protein is the main regulator of CF, but also 
showing that there are other factors involved. Finally, therapies that enhance and inhibit 
the function of normal CFTR protein are currently being employed depending on the 
extent of the phenotype and its manifestations. Drugs target the defective protein 
alongside therapies based on the amount of functioning CFTR in the cells in order to 
maintain homeostasis of the body. By analyzing the defective CFTR protein and its 
causes, as well as phenotypic manifestations of CF, I have come to understand the 
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CFTR Protein Outcome Severity of Phenotype 
I 10% No CFTR High 
II 70% Defective Processing High 
III 2-3% Defective Regulation  High 
IV <2% Altered Conductance Reduced 

















































































































































































Table 1: Mutation Classes and their Characteristics 
This table shows the four main classes of mutations of the Cystic Fibrosis 
Transmembrane Conductance Regulator Gene. The first three represent the most severe 
phenotype or clinical manifestations of the disease, and this is due to no CFTR, or 
defective CFTR processing or regulation. The second two classes of mutations show a 
difference in that they cause altered conductance, and less CFTR is made overall; these 





Figure 1: The Structure of the Cystic Fibrosis Transmembrane Conductance Regulator 
Protein 
This figure shows the CFTR protein and its domains. It is a glycoprotein consisting of 
two membrane-spanning domains, two nucleotide-binding domains (NBD1 and NBD2) 
that bind and hydrolyze ATP, and a regulatory (R) domain that gates the channel by 
phosphorylation. It is an ATP-binding cassette (ABC) transporter composed of five 
domains: two transmembrane domains (TMD11/TMD2) that form the channel pore, one 
regulatory domain (R), and two nucleotide binding domains (NBD1/NBD2). 
Phosphorylation of the R domain by protein kinase A and recruitment of ATP to the 
nucleotide binding domains NBD1 and NBD2 causes opening of the channel. These 
domains bind and open to the channel pore. In other words when ATP binds at the 
interface between NBD1 and NBD2, the channel conforms to be open. When ATP 
hydrolyzes, the NBDs dissociate to close the channel, and ATP activity thus promotes a 
dissociation of the NBDs, causing the channel to close. This is the overall process of 
“gating” occurring to open and close the channel, and it allows for the necessary chloride 
transport and conductance in and out of the cell.  
Key: 
MSD=membrane spanning domain 
NBD=nucleotide-binding domain 
 
Figure 2: Normal CFTR Conductance 
This figure shows that when the chloride channel is functional, it causes efflux of 
chloride ions out of the cell, thus regulating the balance of ions and keeping the 
mucociliary clearance system of the airways intact.  
 
Figure 3: Defective CFTR Conductance 
 38 
When the CFTR channel is dysfunctional, chloride ions cannot properly leave the cell, 
causing a lack of appropriate conductance and a buildup of viscous mucous in the 
airways. This figure shows a chloride channel that is closed and thus acts as a locked gate 




Figure 4: Immunity 
This figure shows the divide between innate and adaptive immune responses in the body 
and the main cells that are involved in the immune response. The innate immune system 
includes the release of leukocytes, or white blood cells, which then target areas of the 
body that are infected and lead to a cycle of infection and inflammation in patients with 
CF. The adaptive immune system involves B and T cells, which are antigen-specific and 
require a response from specific antibodies for effective pathogenic clearance, and are 
seen in higher levels in CF patients.  
 
 
 
 
 
 
 
 
 
 
